When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
Principia Biopharma (PRNB) is a small-cap biopharma with its lead candidate in phase 3 targeting pemphigus vulgaris or PV, an autoimmune disease causing dermal or mucosal blisters. There are existing medications, but treatment may take years, so people often use a lower dose of medication not to cure but to make sure the sign and symptoms of the disease do not occur.
PRNB's lead drug candidate PRN1008 is a second generation BTK inhibitor which is claimed to be as potent as the earlier generation but with less of the side effects. This claim